Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma

Journal of the National Cancer Institute

Volumn 96, Issue 13, 2004, Pages 1006-1014

  Cuccuru, Giuditta ^a   Lanzi, Cinzia ^a   Cassinelli, Giuliana ^a   Pratesi, Graziella ^a   Tortoreto, Monica ^a   Petrangolini, Giovanna ^a   Seregni, Ettore ^a   Martinetti, Antonia ^a   Laccabue, Diletta ^a   Zanchi, Chiara ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIHYDRO 5,6 DIMETHOXY 3 [(4 HYDROPHENYL)METHYLENE] 1H INDOL 2 ONE; CALCITONIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RPI 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; ONCOPROTEIN; PHOSPHOLIPASE C GAMMA; PROTEIN RET; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RET PROTEIN, HUMAN; RPI 1 CPD; RPI-1 CPD;

AGAR MEDIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; FEMALE; FIBROBLAST; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; MOUSE; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; ONCOGENE RET; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; MEDULLARY CARCINOMA; METABOLISM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; SERODIAGNOSIS; SIPPLE SYNDROME; THYROID TUMOR; WESTERN BLOTTING; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, MEDULLARY; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INDOLES; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; ONCOGENE PROTEINS; PHOSPHOLIPASE C; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PRECIPITIN TESTS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 3242735120     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh184     Document Type: Article

References (42)

1. Fraker DL, Skarulis M, Livolsi V. Thyroid tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia (PA): Lippincott; 2001. p. 1740-62.
2. Lairmore TC, Wells SA, Moley JF. Molecular biology of endocrine tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia (PA): Lippincott; 2001. p. 1727-40.
3. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Internal Med 2003;253:616-26.
4. Wells SA, Franz C. Medullary carcinoma of the thyroid gland. World J Surg 2000;24:952-6.
5. Bongarzone I, Pierotti MA, Monzini N, Mondellini P, Manenti G, Donghi R, et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989;4:1457-62.
6. Jhiang SM. The RET proto-oncogene in human cancer. Oncogene 2000; 19:5590-7.
7. Ponder BA, Smith D. The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res 1996;70:179-222.
8. Michiels FM, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, et al. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci U S A 1997;94:3330-5.
9. Acton DS, Velthuyzen D, Lips CJ, Hoppener JW. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 2000;19:3121-5.
10. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001;12:361-73.
11. Takahashi M, Buma Y, Taniguchi M. Identification of the ret protooncogene products in neuroblastoma and leukaemia cells. Oncogene 1991; 6:297-301.
12. Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, et al. Dual effect on RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. Oncogene 1998;17:2851-61.
13. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, et al. Biological properties of Ret with cysteine mutations correlate with multiples endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 1997;57:2870-2.
14. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 1999;18:3919-22.
15. Lanzi C, Borrello MG, Bongarzone I, Migliazza A, Fusco A, Grieco M, et al. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. Oncogene 1992;7: 2189-94.
16. Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000;37:817-27.
17. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1:117-23.
18. Lanzi C, Cassinelli G, Pensa T, Cassinis M, Gambetta RA, Borrello MG, et al. Inhibition of transforming activity of ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer 2000;85:384-90.
19. Lanzi C, Cassinelli G, Cuccuru G, Zaffaroni N, Supino R, Vignati S, et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci 2003; 60:1449-59.
20. Carniti C, Perego C, Mondellini P, Pierotti MA, Bongarzone I. PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteasomal targeting. Cancer Res 2003;63:2234-43.
21. Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, et al. RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995;11:2419-27.
22. Carlomagno F, Salvatore D, Santoro M, de Franciscis V, Quadro L, Panariello L, et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 1995;207:1022-8.
23. Shekan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
24. Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, et al. The full oncogenic, activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol 1996;16:2151-63.
25. Yamamoto M, Li M, Mitsuma N, Ito S, Kato M, Takahashi M, et al. Preserved phosphorylation of RET receptor protein in spinal motor neurons of patients with amyotrophic lateral sclerosis: an immunohistochemical study by a phosphorylation-specific antibody at tyrosine 1062. Brain Res 2001;912:89-94.
26. United Kingdom Co-ordinating Committee on Cancer Research (UKC-CCR) Guidelines for the Welfare of Animals in Experimental Neoplasia. (Second Edition). Br J Cancer 1998;77:1-10.
27. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford (U.K.): Blackwell Scientific Publishers; 1987. p. 411-20.
28. Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, Mineo A, et al. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in Ret and Ret-derived oncoproteins. J Clin Endocrinol Metab 2000;85:3898-907.
29. Asai N, Murakami H, Iwashita T, Takahashi M. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. J Biol Chem 1996;271:17644-9.
30. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000;275:3568-76.
31. Besset V, Scott RP, Ibanez CF. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem 2000;275:39159-66.
32. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002;8(4 Suppl):S14-8.
33. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002;62:1077-82.
34. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab 2003;88:1897-902.
35. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62;7284-90.
36. Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 2002;21:2407-17.
37. Buckwalter TL, Venkateswaran A, Lavender M, La Perle KM, Cho JY, Robinson ML, et al. The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation. Oncogene 2002;21:8166-72.
38. Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 2000;19:4469-75.
39. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
40. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001;19:265-72.
41. Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res 2003;9:2389-90.
42. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20:325-34.